Forkhead box protein P1 as a downstream target of transforming growth factor-β induces collagen synthesis and correlates with a more stable plaque phenotype  by Bot, Pieter T. et al.
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Objective:  Atherosclerosis  is an  inﬂammatory  disease,  modulated  by  plaque  stabilizing  and  de-stabilizing
cell  populations  such  as  inﬁltrating  monocytes  and  vascular  smooth  muscle  cells  (vSMCs).  Transcription
factors  regulating  proliferation  and  differentiation  of  atherosclerosis  relevant  cell  types  are  of  interest  in
this  context.  The  forkhead  box  transcription  factor  FoxP1  modulates  monocyte  differentiation.  We studied
FoxP1 expression  in  atherosclerotic  tissue,  correlated  FoxP1  expression  with  plaque  characteristics  and
identiﬁed  associations  between  FoxP1  and  plaque  proteins.
Methods:  116  Atherosclerotic  plaques  from  carotid  endarterectomy  samples  were  histologically  clas-
siﬁed (ﬁbrous,  ﬁbroatheromatous,  atheromatous)  and  subjected  to semi-quantitative  protein  analysis.
Macrophage,  SMC  content  and  intraplaque  thrombus  amount  were  determined  histologically.  FoxP1
expression  was  investigated  by  western  blotting  and immunohistochemistry.  In  addition  FoxP1  was
overexpressed  in  vitro to identify  causal  relations  between  FoxP1  and  plaque  proteins.
Results:  FoxP1  expression  was  observed  in  SMCs,  macrophages,  endothelial  cells  and  T-cells  within  the
plaque.  High  SMC  and collagen  content  correlated  with  increased  FoxP1  isoform  (72  kD  and  95 kD)  levels.
72 kD FoxP1  expression  was  lower  in plaques  containing  intraplaque  thrombus.  FoxP1  correlated  with
active  intraplaque  TGF  signaling.  In  vitro  stimulation  of  SMCs  with  TGF  resulted  in increased  FoxP1
levels.  72  kD  FoxP1  correlated  with  expression  of  pro-ﬁbrotic  EGR-1  and  increased  Col1A1 expression.
Conclusion:  FoxP1  is  expressed  by  different  cell  types  in  atherosclerotic  lesions  and  associated  with  more
stable  plaque  characteristics  and  intraplaque  TGF  signaling.  FoxP1  expression  in  vitro  is  induced  by
TGF,  resulting  in  increased  collagen  and  EGR-1  expression,  providing  a  mechanism  for  the  observed
association  with  a more  stable  plaque  phenotype.. IntroductionAtherosclerosis is uniformly conceived as an inﬂammatory dis-
ase of the arteries [1,2]. Unstable atherosclerotic lesions are
haracterized by lower numbers of smooth muscle cells and a
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reduced ﬁbrous cap covering the lesion, Moreover, these lesions
contain increased numbers of inﬂammatory cells [2]. The inﬁl-
tration of circulating monocytes into the vascular wall and their
differentiation to plaque macrophages is a critical component in the
initiation and progression of atherosclerotic lesion development
[3].  Transcription factors regulating proliferation and differentia-
tion of atherosclerosis relevant cell populations are of interest in
inﬂuencing atherosclerotic plaque stability towards a more stable
Open access under the Elsevier OA license.or unstable phenotype. Recently, the forkhead box transcription
factor FoxP1 was described as a key modulator of macrophage dif-
ferentiation [4] and we  now hypothesized that FoxP1 could be an
important transcriptional regulator of atherogenesis.
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Table 1
Baseline characteristics.
Variable (n = 126)
Age (yr) 64.5 ± 8.4
Sex (%)
Female 29.9
Male 70.1
Diabetes (%) 16.0
High blood pressure (%) 69
Hyperscholesterolemia (%) 53.9
Smoking (%) 31.4
Statine use (%) 65.1
Beta-blocker use (%) 49.2
Anticoagulant use (%) 15.1
Calcium antagonist use (%) 23.0
ACE-inhibitor use (%) 41.34 P.T. Bot et al. / Athero
FoxP1 was ﬁrst identiﬁed by Shu et al. as a glutamine rich fac-
or that is expressed in a wide variety of adult and fetal tissues cell
ypes and belongs to the FoxP subfamily of the fox-transcription
actors [5].  Misregulation of FoxP1 is seen in several malignant neo-
lasms, including prostate cancer and B-cell lymphomas [6]. With
egards to macrophage biology, FoxP1 has been shown to impair the
ransition of monocytes towards macrophages and acts as a repres-
or of c-fms, which codes for the receptor of the differentiation
timulating growth factor M-CSF (Macrophage Colony Stimulating
actor). Inﬂammatory cells are a major component of atheroscle-
otic lesions and inﬁltration of monocytes, and T-lymphocytes can
lready be observed in early lesions and fatty streaks [3].  The mat-
ration of inﬁltrating monocytes towards tissue macrophages and
ventually lipid-containing foam cells is a critical step in plaque
rogression, and the signaling events that control differentiation
nd survival of plaque resident macrophages are largely unknown.
ecently, FoxP1 was implicated in the process of macrophage mat-
ration and was described to regulate monocyte differentiation in
esponse to integrin-engagement [4].
Furthermore, FoxP1 has been shown to be involved in cardiac
uscle cell proliferation and differentiation, in which differen-
ial effects of FoxP1 in early and late cardiac development were
bserved [7].  The role of FoxP1 in vascular smooth muscle prolif-
ration has not been described so far, although this indicates that
oxP1 is a transcriptional mediator of proliferation and differenti-
tion in different atherosclerosis relevant cell types [8]. As the pro-
ess of muscle cell proliferation and differentiation is regulated by
ownstream effects of growth factors like TGF- and FGF, we rea-
oned FoxP1 might be a downstream target of these growth factors.
FoxP1 might be further of inﬂuence on inﬂammatory plaque
haracteristics, by inﬂuencing the expression pro-inﬂammatory or
nti-inﬂammatory proteins [4].  Besides c-fms, other downstream
argets of FoxP1 however have been poorly described. Recently,
 binding site of FoxP1 in the Interleukin-2 promoter region has
een reported [9],  but the exact effect of FoxP1 on interleukin
xpression is incompletely understood. Although some evidence is
ointing towards a downregulatory effect of FoxP1 overexpression
n speciﬁcally IL2, Bettelli et al. were not able to demonstrate an
ffect of FoxP1 overexpression on IL-2 expression [10]. The asso-
iation of interleukins and plaque stability has been described in
etail, showing opposing correlations of the different interleukins
nd plaque phenotype. For instance, IL-10 expression is higher in
table plaques whereas IL-8 expression is increased in unstable
esions [11]. Thus, FoxP1 might be relevant for the modulation of the
ntraplaque inﬂammatory balance by inﬂuencing the expression of
ifferent interleukins.
In this study we aimed to investigate the meaning of FoxP1
xpression in atherosclerosis by examining the expression pat-
ern of FoxP1 in atherosclerotic lesions and the correlation of its
xpression with the severity of atherosclerosis.
. Materials and methods
.1. Study design: the Athero-Express
The Athero-Express is a large multicenter patient study in which
ndarterectomy specimens are collected and characterized in com-
ination with follow-up data. Medical ethical committees of all
utch participating centers approved the study [12]. Each patient
igned an informed consent form. Table 1 shows the baseline char-
cteristics of the randomly selected patients for the current study..2. Immunohistochemistry
The culprit lesion of 116 plaques was cut into 5 m sec-
ions for histological analysis of plaque phenotype, the amountPlatelet aggregation inhibitor use (%) 95.2
Symptomic patients (%) 88.2
of intraplaque thrombus and collagen, smooth muscle cells,
macrophages and fat content and classiﬁed as moderately, heav-
ily or not stained as previously described [12]. As for the
phenotype classiﬁcation, plaques were divided into a ﬁbrous, ﬁbro-
atheromatous and an atheromatous group, as described previously
[12]. The adjacent segment was  used for protein isolation.
For histological evaluation of FoxP1 expression in different
arterial wall layers of an atherosclerotic diseased vessel, after
deparafﬁnation and rehydration, endogenous peroxidase activity
was blocked with methanol containing 0.3% peroxide. Heat-
induced antigen retrieval was  performed using 10 mM Tris-HCl and
1 mM EDTA, pH 9.0. Then sections were covered with serum-free
protein block (Dako), followed by different primary antibodies. We
stained the plaques for mouse anti-human FoxP1 (JC12, Abcam),
rabbit anti-human CD3 (SP7; Labvision, Fremont, CA), mouse anti-
human CD68 (PGM1, Dako) and mouse anti- alpha-smooth muscle
cell-actin (1A4, Sigma–Aldrich). As a secondary agent we  used
Envision anti-rabbit (Dako) or Poly-AP anti-mouse (Immunovision
Technologies, Brisbane, USA). As chromogens we used DAB and
Liquid Permanent Red Kit (both from Dako).
2.3. FoxP1 protein expression levels
Of every patient we used 10 g plaque protein, isolated as previ-
ously described, [12] which was reduced using 0.1 M DTT and 5 min
of cooking. Proteins were run on a 10% polyacrylamide gel. Four l
of protein from cultured human monocytes (THP-1 cells) served
as a positive control. After gels were run at 30 mA during 45 min,
proteins were blotted on a Immobilon-FL transfer membrane (Mil-
lipore).
The membrane was  blocked for 1 h at room temperature using
3% non-fat dry milk in PBS containing 0.1% Tween. Afterwards,
the membranes were incubated overnight with a rabbit polyclonal
FoxP1 antibody (0.15 g/ml, ab16645, Abcam). A HRP-labeled
goat-anti rabbit secondary antibody (P0447, Dako) was  used at
a concentration of 1 g/ml. ß-Actin (clone AC-74, Sigma) expres-
sion levels were used to correct for the intraplaque cell number as
previously described [13].
2.4. Inﬂuence of the TGF co-receptor endoglin and TGF on FoxP1
expression
We cultured Human aortic SMCs (HA-SMCs, CRL-1999, Amer-
ican Type Culture Collection) according to the manufacturer. We
used an adenoviral endoglin RNAi construct at a multiplication of
infection (MOI) of 250 to inhibit endoglin expression as described
previously [13]. Adenoviral GFP was  used as a control. Cells were
washed after 16 h and allowed to recover for 24 h prior to starva-
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Fig. 1. FoxP1 positive cells in different layers of an atherosclerotic artery (A–C). Expression was especially high in the media (1B). FoxP1 positive SMCs (D–F) were observed
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n  T-cells (J and K). Nuclear staining in blue, FoxP1 nuclear staining in brown; CD3
eferences to color in this ﬁgure legend, the reader is referred to the web  version of
ion overnight before we stimulated with TGF1 (1 ng/ml) for 0,
 h or 24 h. After washing twice with PBS, we isolated total cell
rotein using Tripure Isolation Reagent (Roche). Furthermore, we
nalyzed the effect of inhibiting TGF signaling using the ALK5
inase inhibitor on FoxP1 expression. For this the ALK5 kinase
nhibitor (SB-431542) was added to the cell culture in a ﬁnal con-
entration of 1 M in combination or in absence of 24 h of TGF
timulation (0.5 ng/ml) as described previously [14]. FoxP1 expres-
ion was analyzed using western blots as described above.
.5. Inﬂuence of FoxP1 knock-down on TGF  ˇ induced vascular
mooth muscle cell proliferation
VSMC were seeded in a 96-well ELISA plate in 100 l 10%
MC  medium in 2 different concentrations: 0.5 × 104 and 1 × 104
ells per well. The next day the cells were transfected, using lipo-
ectamine rnaimax, with siRNA foxp1 #2 and #6 as well as an
ntransfected control condition. After 5 h, the media was changed
o 100 l of 10% SMC  with heat-inactivated FBS and incubated
vernight at 37 ◦C. In the morning the media was changed to 100 l). We observed FoxP1 staining in macrophage (H and I) and to a much lesser extent
8 and alpha smooth muscle cell positive staining in red. (For interpretation of the
rticle.)
of 10% SMC  with heat-inactivated FBS plus 10 l BrdU-labeling
solution; also, plus or minus TGF (1 ng/l). On day 4, the ELISA
was performed according to the Roche protocol.
2.6. FoxP1 in vitro overexpression and quantitative RT-PCR of
downstream targets
Transfection of HEK-293 cells with a FoxP1 plasmid was per-
formed as described previously [13]. We  seeded Human Embryonic
Kidney (HEK) 293 cells (ATCC: CRL-1573.) in a 12 well plate and
grown until 80% conﬂuency in DMEM supplemented with 10%
Fetal Calf Serum, 1% Penicillin/Streptomycin. We  washed the cells
twice with PBS and then added 0.4 ml  of serum free DMEM. Using
LipofectamineTM Plus (Invitrogen), we transfected cells with 0.4 g
FoxP1 plasmid (n = 4) or an equal amount of GFP-vector as control
(n = 4).To provide insights into the consequences of increased expres-
sion of FoxP1 in an in vitro model, we  analyzed which downstream
targets are affected. We  developed primers directed against com-
ponents of the TGF signaling pathway. All expression levels
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ere corrected for GAPDH expression. In Table 1 the different
rimer sequences are depicted. Functionality of the FoxP1 plasmid
as tested by analyzing FoxP1 expression levels in FoxP1 trans-
ected cells compared to GFP-transfected cells, using FoxP1 speciﬁc
rimers.
.7. Statistical analysis
Data are presented as mean and 95% conﬁdence interval.
s our data was not-normally distributed, we  used the non-
arametric Mann–Whitney (for comparison of two categories) or
ruskal–Wallis tests (for comparison of 3 or more categories).
orrelations were analyzed using the Spearman–Rank Test. For
he statistical analysis of the in vitro experiments we  used a
ann–Whitney test. P-Values of <0.05 were considered signiﬁcant.
. Results
.1. FoxP1 is expressed in atherosclerotic lesions by different cell
ypesAs depicted in Fig. 1A–C, we observed FoxP1 expression in dif-
erent vascular layers of atherosclerotic vessel. FoxP1 staining was
ainly restricted to the nucleus of cells in the intima, the media
nd adventitia, with most pronounced staining in the media.inued )
Using double staining techniques, we  indeed observed intranu-
clear staining of FoxP1 in smooth muscle cells in the different
vascular layers, with most of these cells expressing FoxP1
(Fig. 1D–F). Using double staining for CD34 and FoxP1 we  also
observed co-localization in the majority of endothelial cells
(Fig. 1G), which might indicate a stabilizing effect of FoxP1 on
vascular integrity, as knock-down of FoxP1 has been described
to result in severe perivascular hemorrhage [15]. Furthermore,
although expression levels of FoxP1 have been shown to decrease
after the transition of monocytes to macrophages [4],  we still
observed FoxP1 expression in macrophages as these cells were dou-
ble stained for FoxP1 and CD68 (Fig. 1H and I). Using CD3 staining,
we analyzed if FoxP1 is expressed by T-cells, but only a minority of
T-cells in the atherosclerotic vessel express FoxP1 (Fig. 1J and K).
3.2. FoxP1 expression is higher in ﬁbrous plaques
In a second step we  analyzed if FoxP1 expression would differ
in plaques with a ﬁbrous phenotype compared to an atheromatous
phenotype, generally regarded as more unstable [2,16].  Using west-
ern blots, we  observed two separate bands of FoxP1-expression, a
95 kD isoform as well as a 72 kD isoform, which showed a signiﬁcant
correlation in expression levels (p < 0.001, correlation coefﬁcient
.609). For the 95 kD FoxP1 isoform, expression was signiﬁcantly
higher in plaques with a ﬁbrous phenotype, compared to the more
P.T. Bot et al. / Atherosclerosis 218 (2011) 33– 43 37
Fig. 2. FoxP1 expression correlated to histological plaque characteristics. Plaques with a ﬁbrous phenotype showed increased expression of the 95 kD isoform of FoxP1,
compared to atheromatous plaques (A). Deﬁnition of different plaque phenotypes was previously described [12]. For the 72 kD FoxP1 isoform we observed an non-signiﬁcant
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(rend  towards a positive correlation with a more ﬁbrous plaque phenotype (B). Bot
igniﬁcant correlation was  observed between FoxP1 expression and the macrophag
ith  unstable plaques, showed a negative correlation with FoxP1 expression (F and
theromatous plaques (p = 0.049). The expression of the 72 kD iso-
orm showed a non-signiﬁcant increased expression in ﬁbrous
laques compared to atheromatous plaques (p = 0.166). (Fig. 2A and
).
Plaques containing a high smooth muscle cell content revealed
igniﬁcantly higher expression levels of both isoforms (for
oxP1, 72 kD: p = 0.027, correlation coefﬁcient = .211, FoxP1, 95 kD:
 = 0.026, correlation coefﬁcient = .201) (Fig. 2C and D). Neither the
5 kD nor the72 kD isoform of FoxP1 was signiﬁcantly correlated
o intraplaque macrophage content (p = 0.199 resp. 0.278) (Fig. 2E
nd F).
A factor with a strong association with plaque instability, the
mount of intraplaque thrombus [17,18], was negatively correlated
ith the 72 kD isoform of FoxP1 (p = 0.002). For the 95 kD vari-
nt, we observed a trend towards a negative correlation (p = 0.106)
Fig. 2G and H).orms of FoxP1 were signiﬁcantly correlated to the amount SMCs in the plaque. No
tent of the plaque (C–E). The amount of intraplaque thrombus, which is associated
 p < 0.05.
3.3. FoxP1 and TGF  ˇ signaling
Both the FoxP1 isoform of 95 kD as well as the 72 kD isoform cor-
related to the phosphorylated TGF transcription factor pSMAD2
(with respectively a correlation coefﬁcient: 0.500, p < 0.01, and cor-
relation coefﬁcient: 0.609, p < 0.01), indicating that FoxP1 might be
a downstream target of TGF or that FoxP1 stimulates TGF expres-
sion (Fig. 3A and B). We  did not ﬁnd evidence for a stimulating
effect of FoxP1 overexpression on TGF expression levels, whereas,
in vitro stimulation of vSCMs with TGF led to an upregulation of
both FoxP1 isoforms (Fig. 3C and F). Additionally, knock-down of
FoxP1 using siRNA resulted in signiﬁcantly decreased TGF induced
vascular smooth muscle cell proliferation (Fig. 3I).
To further analyze the role of FoxP1 in TGF signaling we ana-
lyzed the correlation of FoxP1 expression in the plaque and the
expression of the TGF co-receptor endoglin [19–21].  The 72 kD
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soform of FoxP1 correlated positively to the TGF co-receptor
ndoglin (p < 0.05), which could be due to a stimulatory effect of
oxP1 on endoglin expression or a downstream effect of endoglin
xpression on FoxP1 signaling (Fig. 3D and E). Interestingly, in
he absence of endoglin using RNAi, TGF failed to induce FoxP1
xpression. In vitro overexpression of FoxP1 resulted in a 3.3-fold
ncrease in endoglin mRNA levels (p < 0.05), suggesting a primarily
odulatory effect of FoxP1 on TGF signaling (3G). Inhibition of the
LK5 receptor led to the absence of a stimulatory effect of TGF on
oxP1 95 kD expression, while no signiﬁcant effect was  observed
n FoxP1 72 kD expression (Fig. 3H).
.4. FoxP1 expression correlates to IL2, Il-4 and IL-10
Interestingly, the expression level in the plaques of the 95 kD
and of FoxP1 correlated positively with three different inter-
eukins, both the anti-inﬂammatory interleukins IL-4 (p = 0.034,
orrelation coefﬁcient: .202) and IL10 (p = 0.026, correlation coef-
cient: .212) as well as the pro-inﬂammatory IL-2 (p = 0.037,
orrelation coefﬁcient: .199, n = 110) (4A-C). As FoxP1 is known as
 transcriptional repressor [5],  these positive associations might
e indirect and caused by inhibition of another repressing factor.
n vitro, we analyzed the causal effect of an increase in FoxP1 levels,
hich led to a 5-fold increase in IL-2 levels (p < 0.05) and a 10.2-fold
ncrease in IL-4 (p < 0.05) (Fig. 4D and E). IL-10 levels were below
etection limit.inued )
3.5. FoxP1 and smooth muscle cell and collagen content
Based on our ﬁnding that the expression levels of both FoxP1
isoforms are signiﬁcantly higher in SMC  rich lesions, we analyzed
the potential mechanism for this observation. FoxP1 72 kD corre-
lated signiﬁcantly to the transcription factor EGR-1 (correlation
coefﬁcient = 0.292, p = 0.041), which has been shown to stimu-
late smooth muscle cell proliferation as well as collagen synthesis
(Fig. 4F) [13,22,23].  The 95 kD FoxP1 isoform was not signiﬁ-
cantly correlated to EGR-1 expression. In vitro, we  demonstrated
that increased FoxP1 levels resulted in a signiﬁcantly 2.5 fold
increased EGR-1 expression (p < 0.05), suggesting that FoxP1 might
increase smooth muscle proliferation by upregulation of EGR-1
(Fig. 4G). As smooth muscle cells are an important source of colla-
gen production, and a high percentage of the smooth muscle cells
stained positive for FoxP1, we  analyzed if FoxP1 affected collagen
production. We  observed a 1.7-fold increase signiﬁcant increase
in Col1A1 mRNA levels after FoxP1 overexpression (p = 0.011)
(Fig. 4H).
4. Discussion
To the best of our knowledge, this is the ﬁrst study to demon-
strate that FoxP1 is a transcription factor downstream of TGF,
which is expressed by different cell types in atherosclerotic lesions.
In atherosclerotic plaques FoxP1 was  mainly expressed by smooth
muscle cells and endothelial cells, although we  also observed sub-
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Fig. 3. Association of FoxP1 expression and the TGF signaling pathway. Both isoforms of FoxP1 correlated signiﬁcantly with the activated form of the downstream tran-
scription factor of TGF, phosphorylated SMAD-2 (A and B) suggesting the involvement of FoxP1 in the TGF-beta signaling pathway. This was not mediated by an increase
in  TGF-levels by FoxP1 as in vitro overexpression of FoxP1 did not lead to an increase in TGF mRNA. (C). A positive correlation between the 72 kD FoxP1 isoform and the
TGF  co-receptor endoglin was observed, suggesting a modulating effect of TGF signaling via its co-receptor, endoglin (D and E). Indeed, RNA inhibition of endoglin resulted
in  the inability of TGF to induce FoxP1 expression (mainly the 72 kD variant) (F). Additionally, in vitro overexpression of FoxP1 resulted in increased mRNA expression of
endoglin, suggesting a positive feed back mechanism (G). Vascular smooth muscle cells failed to increase FoxP1 95 kD expression after TGF stimulation in the presence of
a  ind
T 0.05. N
s
t
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an  ALK5 kinase-inhibitor, strengthening the idea of a crucial role for endoglin in TGF
GF  induced stimulation of vascular of smooth muscle cell proliferation (I). * = p < 
tantial staining by macrophages and to some extent by T-cells. As
he staining pattern of this transcription factor was  mainly nuclear
nd not cytoplasmatic, FoxP1 most likely also signals actively in
he atherosclerotic plaque. FoxP1 expression correlated to active
ntraplaque TGF signaling as the levels of the activated form of
he transcription factor downstream of TGF, pSMAD2 [24] showed
 highly signiﬁcant correlation to FoxP1. In vitro, using cultureduced FoxP1 expression (H) Knock-down of FoxP1 using siRNA resulted in decreased
on-categorical data are divided into equal tertiles for graphical representation.
vascular smooth muscle cells, we were able to increase FoxP1 lev-
els after addition of TGF, indicating a stimulatory downstream
effect of this growth factor on FoxP1. Several lines of evidence sug-
gest a plaque stabilizing role for TGF, although the mechanism
by which TGF promotes plaque stability are presently unknown
[13,22,25]. We  suggest that FoxP1 is in part responsible for these
effects. A limitation of this study is the relatively low correlation
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oefﬁcients which are consistent with a heterogeneous disease pro-
ess as atherosclerosis is.
In our carotid artery specimens we detected two isoforms of
oxP1, a 95 kD and a 72 kD variant. Previous studies suggest that
he FoxP1 protein diversity is increased due to alternative splicing
26]. The 95 kD variant showed a signiﬁcantly increased expression
n ﬁbrous plaques, compared to atheromatous and ﬁbroatheroma-
ous phenotypes In vitro we were able to demonstrate a stimulatory
ffect of FoxP1 overexpression on collagen-synthesis as the expres-
ion of Col1A1 mRNA levels increased after overexpression of
oxP1, further implying a stabilizing effect of FoxP1 on atheroscle-
otic plaques. Recently, in the ﬁbrotic pathological process of heart
ailure, FoxP1 expression was shown to be increased [27], which
upports a ﬁbrosis stimulating role of FoxP1. A signiﬁcant pos-
tive correlation between the FoxP1 isoform of 72 kD and the
ntraplaque levels of the pro-ﬁbrotic transcription factor EGR-1
rovides additional evidence for a potential stabilizing role of FoxP1
n atherosclerosis [13,22].A  highly signiﬁcant correlation of both FoxP1 isoforms and the
ctivated form of the intracellular effector of TGF, pSMAD2 put
orward the involvement of FoxP1 in the TGF signaling cascade.
his could either imply that FoxP1 stimulates transcription of TGF,inued )
leading to increased phosphorylation of pSMAD2, or that FoxP1 is
a downstream effector of TGF. We  did, however, ﬁnd evidence
for the second suggestion only, as FoxP1 overexpression did not
lead to increased TGFmRNA levels. The TGF co-receptor endoglin,
known to modulate the downstream signal of TGF [20,21] also
signiﬁcantly correlated to FoxP1 72 kD expression levels. We did
observe a signiﬁcant increased expression of both endoglin and
EGR-1 levels after FoxP1 overexpression, which is in line with
the observed associations in our patient material. These ﬁndings
might indicate that the upregulation of EGR-1 after FoxP1 over-
expression was not mediated via an increase in TGF levels, but
more likely by a modulatory effect on TGF signaling by upreg-
ulation of the TGF co-receptor endoglin. Inhibition of endoglin
expression using RNAi, abolished the stimulatory effect of TGF
on FoxP1 expression, which was  especially the case for the 72 kD
isoform. This implies that besides a stimulatory effect of FoxP1
on endoglin expression, the expression of endoglin is obligatory
for the stimulatory effect of TGF on FoxP1-expression. Further-
more, using a downstream blocker of TGF signaling, the ALK5
kinase-inhibitor SB-431542, we observed decreased levels of FoxP1
after TGF stimulation compared to control cells that were only
stimulated with TGF. Although FoxP1 has been described mainly
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Fig. 4. FoxP1 association with plaque stability mediating proteins. Downstream effects of FoxP1. FoxP1 95 kD correlated with interleukin-2, 4 and 10 (A–C) and in vitro
overexpression of FoxP1 resulted in increased IL-2 and IL-4 mRNA levels (D and E). FoxP1 (72 kD variant) expression was also associated with the expression of the TGF
t erexp
r  p < 0.
a
t
t
ﬁ
c
e
o
eranscription factor EGR-1, which is involved in smooth muscle proliferation. (F). Ov
esulted in increased Col1A1 mRNA levels, suggesting a ﬁbrotic effect of FoxP1 (H) * =
s a transcriptional repressor [6,28],  potentially it also possesses
he capacity to stimulate the expression of several downstream
argets. On the other hand, another possible explanation for our
ndings would be that FoxP1 represses an unknown target which
ontains inhibitory effects on endoglin or EGR-1 expression lev-
ls. This remains to be elucidated. Potential other downstream
r upstream regulatory mechanisms of FoxP1 expression include
ffects of FoxP1 on NF-kappaB expression, although a causal inter-ression of FoxP1 also resulted in increased EGR-1 levels (G). FoxP1 overexpression
05. Non-categorical data are divided into equal tertiles for graphical representation.
action of these transcription factors has not been identiﬁed so far.
Of interest is the recent observation that overexpression of FoxP3
results in decreased NF-kappaB expression [29]. The FoxP3 fork-
head domain shares high sequence similarity with two  other FoxP
family members FoxP1 and FoxP2, and co-operates with FoxP1 and
FoxP2 by means of heterodimerization. Based on these ﬁndings
one can speculate on a potential interaction between FoxP1 and
NF-kappaB, thereby modulating plaque stability characteristics.
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As TGF and EGR-1 have been demonstrated to increase smooth
uscle cell proliferation [23,24],  we analyzed the correlation of
oxP1 and intraplaque smooth muscle cell content. We  observed
 positive association of both FoxP1 isoforms and a high smooth
uscle cell content. This association could be due to the involve-
ent of FoxP1 in smooth muscle cell proliferation, partly mediated
y its effect on EGR-1 expression. These data indicate that FoxP1
ould stimulate intraplaque smooth muscle cell content by increas-
ng smooth muscle cell proliferation by upregulation of EGR-1.
nock-down of FoxP1 diminished the capacity of TGF to induce
ascular smooth muscle cell proliferation, further demonstrating
he involvement of FoxP1 in vascular smooth muscle cell prolifer-
tion.
The 72 kD FoxP1 variant was negatively correlated to the
mount of intraplaque thrombus. Also knock-down of FoxP1 has
een shown to result in severe perivascular hemorrhage, suggest-
ng the involvement of FoxP1 in maintaining vascular integrity [15].
his ﬁnding might be of interest in the context of atherosclerosis as
n import feature of unstable plaques is intraplaque hemorrhage,
hich can be caused by vascular leakiness [17,18].
Additionally, the 95 kD isoform of FoxP1 correlated positively
o three different interleukins, IL-2, IL4 and IL10. Although signiﬁ-
ant, we observed a high variation necessitating future studies for
he analysis of the biological relevance of these observations. IL4
nd IL10 are associated with plaque stability whereas the effect
f IL-2 has been discussed controversially [11]. Our observed cor-
elation between FoxP1 and IL-2, Il-4 and IL-10 was  conﬁrmed
n vitro, as FoxP1 overexpression resulted in increased levels of IL-
 and IL-4 (IL-10 levels were below detection limit). This might
ndicate that FoxP1 also has immune modulatory effects in the
laque. Conversely, Wang et al. demonstrated an inhibitory effect
f FoxP1 overexpression on IL-2 levels [9],  whereas Bettelli et al.,
bserved no effect on IL-2 and a non-signiﬁcant increase in IL-4
evels [10]. This might indicate that the effects of FoxP1 on inter-
eukin expression are cell type, context or dose dependent [30]. We
id not, however, ﬁnd a signiﬁcant negative correlation between
oxP1 expression and macrophage content. Although FoxP1 has
een demonstrated to inhibit the transformation from monocytes
nto macrophages [4],  little is known about active FoxP1 signaling
nce these cells become fully matured. It might be that FoxP1 is still
ctive as a transcription factor once these cells are transformed into
ctive macrophages.We conclude that the FoxP1 transcription factor is a transcrip-
ion factor downstream of TGF and is associated with ﬁbrous
laques and collagen synthesis in vitro and might therefore ben-
ﬁcially modulate plaque stability.
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